Barreiro Esther, Salazar-Degracia Anna, Sancho-Muñoz Antonio, Aguiló Rafael, Rodríguez-Fuster Alberto, Gea Joaquim
Pulmonology Department-Muscle and Respiratory System Research Unit, Institut Hospital del Mar d'Investigacions Mèdiques-Hospital del Mar, Parc de Salut Mar, Health and Experimental Sciences Department, Universitat Pompeu Fabra, Barcelona Biomedical Research Park, Barcelona , Spain.
Centro de Investigación en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III , Madrid , Spain.
J Appl Physiol (1985). 2019 Jun 1;126(6):1572-1586. doi: 10.1152/japplphysiol.00670.2018. Epub 2019 Apr 18.
Respiratory muscle dysfunction is common in patients with chronic obstructive pulmonary disease (COPD). Chronic contractile activity induces endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in animals (animals and humans). We hypothesized that the respiratory muscle dysfunction associated with COPD may upregulate ER stress and UPR expression in diaphragm of stable patients with different degrees of airway obstruction and normal body composition. In diaphragm muscle specimens of patients with mild and moderate-to-severe COPD with preserved body composition and non-COPD controls (thoracotomy because of lung localized neoplasms), expression of protein misfolding (ER stress) and UPR markers, proteolysis and apoptosis (qRT-PCR and immunoblotting), and protein aggregates (lipofuscin, histology) were quantified. All patients and non-COPD controls were also clinically evaluated: lung and muscle functions and exercise capacity. Compared with non-COPD controls, patients exhibited mild and moderate-to-severe airflow limitation and diffusion capacity and impaired exercise tolerance and diaphragm strength. Moreover, compared with the controls, in the diaphragm of the COPD patients, slow-twitch fiber proportions increased, gene expression but not protein levels of protein disulfide isomerase family A member 3 and phosphatidylinositol 3-kinase catalytic subunit type 3 were upregulated, and no significant differences were found in markers of UPR transmembrane receptor pathways (activating transcription factor-6, inositol-requiring enzyme-1α, and protein kinase-like ER kinase), lipofuscin aggregates, proteolysis, or apoptosis. In stable COPD patients with a wide range of disease severity, reduced diaphragm force of contraction, and normal body composition, ER stress and UPR signaling were not induced in the main respiratory muscle. These findings imply that ER stress and UPR are probably not involved in the documented diaphragm muscle dysfunction (reduced strength) observed in all the study patients, even in those with severe airflow limitation. Hence, in stable COPD patients with normal body composition, therapeutic strategies targeted to treat diaphragm muscle dysfunction should not include UPR modulators, even in those with a more advanced disease. In stable chronic obstructive pulmonary disease patients with a wide range of disease severity, diaphragm muscle weakness, and normal body composition, endoplasmic reticulum stress and unfolded protein response (UPR) signaling were not induced in the main respiratory muscle. These findings imply that endoplasmic reticulum stress and UPR are not involved in the documented diaphragm muscle dysfunction observed in the study patients, even in those with severe airflow limitation. In stable chronic obstructive pulmonary disease patients with normal body composition, therapeutic strategies should not include UPR modulators.
呼吸肌功能障碍在慢性阻塞性肺疾病(COPD)患者中很常见。慢性收缩活动会在动物(包括动物和人类)中诱导内质网(ER)应激和未折叠蛋白反应(UPR)。我们假设,与COPD相关的呼吸肌功能障碍可能会上调不同程度气道阻塞且身体成分正常的稳定期患者膈肌中的ER应激和UPR表达。在身体成分保持正常的轻度和中重度COPD患者以及非COPD对照组(因肺部局限性肿瘤接受开胸手术)的膈肌标本中,对蛋白质错误折叠(ER应激)和UPR标志物、蛋白水解和凋亡(定量逆转录聚合酶链反应和免疫印迹法)以及蛋白质聚集体(脂褐素,组织学)的表达进行了定量分析。所有患者和非COPD对照组也进行了临床评估:肺功能和肌肉功能以及运动能力。与非COPD对照组相比,患者表现出轻度和中重度气流受限、弥散功能障碍、运动耐力受损以及膈肌力量减弱。此外,与对照组相比,COPD患者的膈肌中慢肌纤维比例增加,蛋白二硫键异构酶家族A成员3和磷脂酰肌醇3激酶催化亚基3型的基因表达上调,但蛋白水平未上调,并且在UPR跨膜受体途径(激活转录因子6、肌醇需求酶1α和蛋白激酶样ER激酶)、脂褐素聚集体、蛋白水解或凋亡的标志物方面未发现显著差异。在疾病严重程度范围广泛、膈肌收缩力降低且身体成分正常的稳定期COPD患者中,主要呼吸肌未诱导出ER应激和UPR信号。这些发现表明,ER应激和UPR可能与所有研究患者中记录到(观察到)的膈肌功能障碍(力量减弱)无关,即使是那些气流严重受限的患者。因此,在身体成分正常的稳定期COPD患者中,即使是那些疾病程度更严重的患者,针对治疗膈肌功能障碍的治疗策略也不应包括UPR调节剂。在疾病严重程度范围广泛、膈肌肌无力且身体成分正常的稳定期慢性阻塞性肺疾病患者中,主要呼吸肌未诱导出内质网应激和未折叠蛋白反应(UPR)信号。这些发现表明,内质网应激和UPR与研究患者中记录到(观察到)的膈肌功能障碍无关,即使是那些气流严重受限的患者。在身体成分正常的稳定期慢性阻塞性肺疾病患者中,治疗策略不应包括UPR调节剂。